Funding Agreement due date extended to November 30, 2022
TherapeuticsMD, Inc. TXMD, (“TherapeuticsMD” or the “Company”), an innovative leader in women’s health, announced today that it has received an additional $7 million private investment from Rubric Capital Management LP in its Series A of the company has received. TherapeuticsMD expects to use the proceeds of the transaction for working capital.
Pursuant to the terms of the Company’s financing agreement with its lender, Sixth Street Specialty Lending, Inc. (“Sixth Street”), upon receipt of the investment and delivery to Sixth Street of warrants to acquire 125,000 common shares of the Company at an exercise price of 0, $01 per share, the maturity date of the financing agreement was automatically extended to November 30, 2022.
The Company’s board and management team continue to actively explore strategic alternatives to strengthen the Company’s long-term financial position.
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is an innovative, leading healthcare company focused on the development and commercialization of novel products exclusively for women. TherapeuticsMD’s products are designed to address the unique changes and challenges women face at different stages of their lives, with a therapeutic focus in the areas of family planning, reproductive health and menopause management. TherapeuticsMD is committed to advancing women’s health and raising awareness of their health issues. To learn more about TherapeuticsMD, please visit https://www.therapeuticsmd.com/ or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.
Cautionary Statements Regarding Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements may include, but are not limited to, statements regarding the Company’s objectives, plans and strategies and statements that are not historical facts and relate to activities, events or…
